Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
Iovance Biotherapeutics
ISIN US4622601007
|WKN A2DT49
Market cap (in EUR)
1,271 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
Overview
Description
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.
Healthcare Biopharmaceuticals Non-System-Specific Biopharmaceuticals United States
Financials
Key metrics
| Market capitalisation, EUR | 1,271 m |
| EPS, EUR | -0.99 |
| P/B ratio | 2.2 |
| P/E ratio | - |
| Dividend yield | 0.00% |
Income statement (2025)
| Revenue, EUR | 234 m |
| Net income, EUR | -347 m |
| Profit margin | -148.38% |
What ETF is Iovance Biotherapeutics in?
There are 23 ETFs which contain Iovance Biotherapeutics. All of these ETFs are listed in the table below. The ETF with the largest weighting of Iovance Biotherapeutics is the WisdomTree BioRevolution UCITS ETF USD Acc.
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.